London Stock Exchange Welcomes Verici Dx plc to AIM


London Stock Exchange welcomes Verici Dx plc (‘Verici Dx’ or the ‘Company’), a developer of advanced clinical diagnostics for organ transplant, to celebrate the listing of the Company's public shares onto AIM, under the ticker "VRCI".

Verici Dx is an immuno-diagnostics development company, initially focused on the kidney transplantation market. The Company's kidney transplant assays will use advanced next-generation sequencing that may define a personalised risk profile of each patient over the course of their transplant journey and may also detect injury in advance of currently available clinical tests.

The Company develops tests to understand how a patient is likely to, and may be, responding to kidney transplant. There are two leading products for clinical validation and commercialisation:

•    Clarava™, which is a pre-transplant prognosis for the risk of early acute rejection; and
•    Tuteva™, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatinine levels.

Verici Dx raised £14.5m gross significantly oversubscribed fundraising with net proceeds being used to undertake clinical utility and validation studies, to bioinformatics and health economic studies as well as staff and related benefits, for general corporate overheads and for license and royalties and capital expenditure (including to build additional testing capacity).

Sara Barrington, CEO of Verici Dx, said: “We are very grateful for the strong support shown by institutional and other investors to the Verici Dx IPO.  Obtaining funding in a public market is a strong signal of quality to prospective partners and customers, raises the profile of the business and its innovative products considerably, and gives us a supportive platform as we advance our strategy.  We look forward to providing further updates on the execution of our validation and commercialisation plans as we deploy the capital raised towards addressing a significant unmet clinical need.”

To find out more about Verici Dx visit:  www.vericidx.com

Quick facts

Track
Market: AIM
Instrument market cap (£m)
63.79
Listing/Admission to trading
03 Nov 2020
Looking for new and recent issues?

More recent

267.6
London Stock Exchange welcomes HSBC Global Asset Management to celebrate the listings of their suite of seven sustainable equity ETFs

Today London Stock Exchange markets were opened by HSBC Global Asset Management to celebrate the listings of their suite of seven Sustainable Equity ETFs.

HSBC Asia Pacific ex Japan Sustainable Equity UCITS ETF
HSBC Developed World Sustainable Equity UCITS ETF
HSBC Emerging Market Sustainable Equity UCITS ETF
HSBC Europe Sustainable Equity UCITS ETF
HSBC Ja

Learn more
115.716
London Stock Exchange Group Celebrates LSEG Foundation’s 10th Anniversary

Today, in addition to officially closing the celebration of LSEG Foundation's 10th Anniversary week, we are honouring our yearly Foundation Day. As part of the event, London Stock Exchange Group will donate the equivalent of two days’ trading fees from our markets, London Stock Exchange, Borsa Italiana and Turquoise to charity. Through LSEG Foundation, the funds raised will help support a wide

Learn more
London Stock Exchange welcomes Round Hill Music Fund Ltd. to the Specialist Fund Segment of the Main Market

Founded in 2010, Round Hill is a fully integrated owner and operator of music copyright properties and the seventh largest music publishing company in the US. Headquartered in New York with additional offices in Nashville, Los Angeles and London, Round Hill has an experienced management and investment team with an established reputation and extensive experience in the music and finance industri

Learn more
73.08
London Stock Exchange welcomes J.P. Morgan Asset Management to celebrate its new sustainable ETF

Today the London Stock Exchange markets were opened by J.P. Morgan Asset Management (JPMAM) to celebrate the launch of JPMorgan Carbon Transition Global Equity UCITS ETF (ticker: JPCT), a sustainable ETF which offers core exposure to global equities with a low tracking error, compared to the MSCI World Index, and have a meaningful reduction in carbon intensity.

JPCT will track the JPM

Learn more